Multiple Assemblies exist for SMTL entry 5v19
Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy; X-RAY DIFFRACTION 3.10 Å

	SMTL ID 5v19.1 Ligands N-(1-ethyl-1H-pyrazol-4-yl)furan-3-carboxamide Polypeptides Mitogen-activated protein kinase kinase kinase 5 Oligo-state monomer
	SMTL ID 5v19.2 Ligands N-(1-ethyl-1H-pyrazol-4-yl)furan-3-carboxamide Polypeptides Mitogen-activated protein kinase kinase kinase 5 Oligo-state monomer